Alternative splicing of pre-mRNAs is a central process to the generation of proteome complexity.
INTRODUCTION
Factor XI (FXI) is a trypsin-like serine protease required for normal hemostasis. It is present in plasma in its precursor form non-covalently bound to high molecular weight kininogen. This zymogen is unique among plasma coagulation enzymes because it exists as a homodimer of 160 kDa composed of 2 identical polypeptide chains held together by both non-covalent interactions and an inter-subunit disulfide bond. Each monomer comprises a light chain, harboring a serine protease catalytic domain, and a heavy chain, consisting of 4 tandem repeats of about 90 residues (termed apple domains, A1 to A4, from the N-terminus), which plays critical roles in protein-protein interactions. 1 FXI can be converted to activated FXI by thrombin, activated factor XII, or by autoactivation.
Cleavage at the Arg369-Ile370 bond in each monomer produces a N-terminal non-catalytic heavy chain and a disulfide-linked C-terminal trypsin-like light chain with a typical catalytic triad His413-Asp462-Ser557. Once activated, FXI contributes to the contact phase of blood coagulation through limited proteolysis of its physiological substrate, factor IX. [2] [3] [4] Human FXI is primarily produced by hepatocytes, although low levels of the transcript are detectable also in platelets, blood mononuclear cells, and granulocytes. 5 Well-washed platelets contain small amounts of FXI, accounting for about 0.5% of the total FXI activity in blood. 6, 7 Three independent groups have reported the partial purification from platelet extracts of a 220-kDa protein (55 kDa in reducing conditions), recognized by anti-FXI polyclonal antibodies and showing FXI activity. [7] [8] [9] The site of synthesis and nature of this platelet variant still remain a matter of debate. 6, 10 The existence of a platelet transcript, originating from the skipping of exon 5, was thought for a long time to account for the a "platelet-specific" FXI isoform, 10 even though the not-in-frame nature of this exon skipping, and the subsequent introduction of a premature termination codon (PTC), was not easily reconcilable with translation after exon 5. Indeed, subsequent studies did not confirm the For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From presence of an alternatively spliced transcript lacking exon 5 in human platelets, in which it was only possible to detect full-length correctly spliced FXI mRNA. 5, 11 Hereditary FXI deficiency is rare in most populations (estimated prevalence of 1 in 1 million), but is particularly common among Ashkenazi and Iraqi Jews, in whom 2 prevalent mutations (Glu117stop and Phe283Leu) account for 98% of alleles. To date, more than 180 mutations, all located in the FXI gene (F11), have been identified and about 30% of them are predicted to cause the introduction of a PTC. [12] [13] [14] It has been estimated that 1/3 of hereditary genetic diseases, as well as many forms of cancer, are caused by mutations that lead to the generation of transcripts bearing a PTC (PTC+ transcripts). 15 The evolutionarily-conserved post-transcriptional mechanism by which PTC+ transcripts are selectively detected and degraded has been called nonsense-mediated mRNA decay (NMD), and is responsible for the elimination of aberrant PTC+ mRNAs generated as a consequence of routine errors in gene expression (such as inefficient or faulty splicing and errors introduced by RNA polymerase II). [16] [17] [18] [19] [20] Furthermore, NMD, through a mechanism called regulated unproductive splicing and translation (RUST), has been experimentally shown to physiologically regulate the expression of a wide variety of genes in many organisms from yeast to humans. [21] [22] [23] Concerning the F11 gene, which is located on chromosome 4q35 and is composed of 15 exons (http://genome.ucsc.edu/, March 2006 release of the human genome, hg18), 24 our group demonstrated the selective degradation of PTCs+ mRNAs in FXI-deficient patients bearing the Glu117stop mutation. 25 Moreover, we recently characterized 2 splicing mutations (325G>A and IVS6+3A>G), both resulting in a frameshift introducing a PTC, which were expected to trigger NMD. Real-time RT-PCR assays, performed to study the effect of these mutations on mRNA stability, revealed the occurrence of multiple aberrant splicing events involving the wild-type F11
pre-mRNA, suggesting the existence of a complex pattern of alternative splicing (AS). 26 In this work we demonstrate that multiple aberrant splicing events involving the wild-type FXI premRNA normally occur in human liver and platelets and are physiologically downregulated by 
METHODS

Human sample preparation
This study was approved by the Institutional Review Board of the University of Milan and was conducted according to the Declaration of Helsinki. Samples were obtained from the analyzed individuals after acquiring appropriate informed consent.
Liver samples were obtained from an Italian female patient with normal FXI levels in plasma, affected by Kasabach-Merrit syndrome, who received a liver transplant. Three biopsies were taken from the healthy parenchyma of the removed liver.
Platelets and plasma were obtained from 3 healthy individuals and prepared as described. 27, 28 All samples were processed immediately after blood withdrawal.
Analysis of the F11 splicing pattern
Total RNA was isolated from HepG2 (human hepatocellular carcinoma) cells, platelets and from human liver by using the RNAWIZ reagent (Applied Biosystems, Foster City, CA, USA).
Random nonamers and ImProm-II Reverse Transcriptase System (Promega, Madison, WI, USA)
were used to perform first-strand complementary DNA (cDNA) synthesis starting from 1 µg of total RNA, according to the manufacturer's instructions. Of a total of 20 µL, 1 µL was used as template for PCR reactions with gene-specific primers. PCRs were carried out under standard conditions using either the FastStart Taq DNA Polymerase (Roche, Basel, Switzerland) or the Ampli Taq Gold DNA polymerase (Applied Biosystems) on a Mastercycler EPgradient (Eppendorf AG, Hamburg, Germany).
The PCR products were cloned into pGEM-T easy vector (Promega) by the TA cloning procedure, 29 and selected recombinant plasmids were sequenced using the BigDye Terminator
Cycle Sequencing Kit v1.1 and an automated ABI-3130XL DNA sequencer (Applied Biosystems).
All primers used in these and in the following experiments are listed in supplementary table 1.
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NMD analysis
HepG2 cells were cultured in RPMI 1640 (Euroclone, Wetherby, UK) supplemented with sodium pyruvate (1 mM; Sigma, St Luis, MO, USA), antibiotics (100 U/mL penicillin and 100 μ g/mL streptomycin; EuroClone), glutamine (2 mM; EuroClone), and 10% fetal bovine serum (HyClone, South Logan, UT, USA), and grown at 37°C in a humidified atmosphere of 5% CO 2 and 95% air, according to standard procedures.
HepG2 were plated at a density of 5.5×10 6 per 10-cm dish and, after 72 hours, treated for 8 hours with puromycin (300 μ g/mL; Sigma), a drug that inhibits NMD by prematurely terminating translation.
After the treatment, cells were washed twice with phosphate-buffered saline (PBS) and total RNA was extracted and reverse-transcribed as described above. Real-time PCR assays were carried out under standard conditions using the iQ5 real-time PCR detection system (Bio-Rad, Hercules, CA, USA) and the iQ SYBR Green Supermix kit (Bio-Rad). In each reaction, 1. 
∆ ∆
CT method, 30 using as reference a transcript not subjected to NMD modulation (i.e., the mRNA for human connexin 32, whose coding sequence is all contained in a single exon).
Quantitation of the
∆
6/7 transcript in human liver and platelets
Absolute quantitative real-time RT-PCR was performed to determine the physiologic expression levels of the splice variant lacking exons 6 and 7 in human liver and platelets. The ratio between exon 6+7-containing and exon 6+7-lacking transcripts was calculated by measuring the absolute quantities of the 2 mRNAs. To this purpose, in order to generate appropriate standard curves, a pcDNA3/FXI-wt+∆6/7 vector (containing 1 copy of the full-length FXI cDNA and 1 copy of the ∆ 6/7 splicing isoform) was constructed. In particular, a plasmid containing the FXI cDNA lacking exon 6 and 7 (pcDNA3/FXI-∆6/7, see further) was used as template in a PCR reaction with the 29 All PCR products were checked by direct sequencing.
Absolute standard curves (spanning at least 3 orders of magnitude) were constructed by using serial dilutions of the pcDNA3/FXI-wt+∆6/7 plasmid.
Expression and quantitation of recombinant
∆
6/7 FXI
The deletion of exons 6 and 7 (270 bp) was introduced in pcDNA3/FXI by a modification of the QuickChange Site-Directed Mutagenesis Kit protocol (Stratagene, La Jolla, CA, USA), as described. 31 The mutant plasmid pcDNA3/FXI-∆6/7 was verified by sequencing the whole FXI FXI antigen levels were evaluated by an enzyme-linked immunosorbent assay (ELISA) based on a goat anti-human FXI affinity-purified IgG as capture antibody and a goat anti-human FXI peroxidase-conjugated IgG as detecting antibody (Affinity Biologicals Inc.), both in conditioned media and in cell lysates, prepared as described above. Standard curves were constructed with reference plasma diluted 1:100 to 1:6,400 in Tris-buffered saline (TBS: 50 mM Tris, 150 mM NaCl, pH 7.5).
FXI coagulant activity was measured in media (collected without protease inhibitor) by a one-stage method based on a modified partial thromboplastin time, using FXI-deficient plasma as substrate (Hemoliance, Salt Lake City, UT, USA). FXI levels were expressed in both tests as percentages of pooled plasma from 30 normal individuals. The detection limits of the FXI functional and immunologic assays were 1% and 0.1%, respectively.
Western blotting analysis
Western blotting analysis on plasma samples, conditioned media, and cell lysates of COS-1 Proteins were detected using a highly sensitive enhanced chemiluminescent substrate (SuperSignal West Dura Extended Duration Substrate; Pierce, Rockford, IL, USA). 
Isolation of the FXI
RESULTS
Characterization of the F11 splicing pattern
A preliminary characterization of the splicing pattern of the F11 gene was performed starting from total RNA isolated from HepG2 cells. To this aim, a set of RT-PCR assays was designed to cover the vast majority of possible AS events (figure 1a).
Multiple AS events were detected (figure 1b, bands marked with an asterisk). In particular, RT-PCR products, on the basis of their electrophoretic mobility, were compatible with: an alternatively spliced product lacking exon 3 (assay A); the skipping of exons 4 (or 6) and 6+7 (assay B); a transcript lacking exon 13 (assay D).
In order to confirm these predicted skipping events, amplified products were T/A-cloned into a plasmid vector and 20 selected recombinant clones for each fragment (A-D) were sequenced: 5 skipping events, involving exons 3, 6, 7, 6+7, and 13 were identified. RT-PCR assays were hence designed to specifically detect each AS product (see supplementary table 1), and performed on RNA from human liver, platelets, and HepG2 cells ( figure 2a-c) . All analyzed AS events were confirmed. The skipping of exons 3, 6, and 7 would determine the introduction of a PTC, located in exons 4, 7, and 10, respectively, whereas, the skipping of exons 6+7 and 13 does not alter the reading frame (figure 2d).
Upregulation of alternatively-spliced transcripts by NMD inhibition
Given that 3 out of 5 F11 skipping events gave rise to a frameshift, eventually leading to the introduction of a PTC, the hypothesis that these alternatively-spliced transcripts were targets of NMD was tested by pharmacological inhibition of this pathway. In particular, protein synthesis inhibitors, such as puromycin, have been proven to block the NMD pathway and are widely used for this purpose. 32 For 
Quantitation of the Δ6/7 transcript
Among the 2 in-frame alternatively spliced transcripts, the one skipping exons 6+7 (FXI-Δ6/7) is not affected by NMD and hence may lead to the synthesis of a FXI isoform with a predicted molecular weight of 140 kDa and differing from the wild-type by the lack of 1 apple domain (i.e. the second half of the A2 and the first half of A3 domain).
Absolute expression levels of the alternative transcript lacking exons 6+7 in physiologic human samples (liver and platelets) were obtained by real-time RT-PCR. Two specific assays were designed to selectively amplify either the ∆ 6/7 or the wild-type mRNA (table S1). In order to generate standard curves for both PCR assays, a new plasmid containing both amplicons (pcDNA3/FXI-wt+∆6/7) was created and used to prepare dilution series (figure 3b). These For personal use only. on September 14, 2017. by guest www.bloodjournal.org From experiments showed that, whereas in liver FXI-Δ6/7 mRNA levels were 19% of the wild-type transcript, in platelets the expression levels of the 2 isoforms were comparable, even though much lower than those detected in the liver (roughly 1:1,000) ( figure 3c-d) .
In-vitro expression of wild-type and Δ6/7 FXIs
To evaluate whether Δ6/7 FXI is synthesized, assembled, and secreted, wild-type and Δ6/7 FXIs were transiently expressed in COS-1 cells (not expressing FXI). As shown in figure 4 , immunoprecipitated Δ6/7 FXI was detectable both intracellularly and extracellularly under nonreducing (upper panels) and reducing (lower panels) conditions as a band with an apparent molecular weight of about 140 and 70 kDa, respectively. In particular, in conditioned media from cells co-expressing wild-type and Finally, to analyze the effects of the ∆ 6/7 deletion (corresponding to residues 145-234) on the functional properties of FXI, the specific activity of secreted FXI was calculated in conditioned media as the ratio between FXI:C and FXI:Ag levels. In supernatants of cells co-expressing wildFor personal use only. on September 14, 2017. by guest www.bloodjournal.org From type and Δ6/7 FXI, the calculated specific activity was reduced (to about 70%) when compared to the wild-type one (figure 5b), whereas in the case of cells transfected with the mutant construct alone, no specific activity was detectable.
Isolation of the Δ6/7 FXI isoform from human plasma
Western blotting experiments on samples immunoprecipitated from human plasma, using both a monoclonal (data not shown) and a polyclonal anti-human FXI antibody, revealed that trace amounts of Δ6/7 FXI isoform were also detectable in plasma, as suggested by the presence of a band with a molecular weight compatible with the lacking of 1 apple domain (figure 6, lane 4).
To confirm this observation, approximately 80 µg of affinity-purified commercial FXI were separated on a 8% SDS-PAGE. After Coomassie staining, full-length FXI was clearly visualized as a sharp band of approximately 80 kDa; in addition a very faint band, possibly corresponding to Δ6/7 FXI isoform, was visible. The bands were excised and submitted to mass spectrometry analysis. A list of candidate proteins was obtained on the basis of their calculated posterior probability. Protein identity was re-verified using isoelectric point, molecular weight, and peptide mass fingerprinting data, as well as comparing them with the SWISS-PROT/NCBI databases. This analysis revealed the presence of tryptic peptides corresponding to human FXI; however, since no fragments distinctive of the deleted isoform are predicted to be generated by tryptic digestion, this analysis could not unequivocally confirm the existence of a FXI ∆ 6/7 protein isoform.
DISCUSSION
Alternative splicing represents a main source of transcriptome and proteome diversity and is therefore relevant to disease and therapy. The use of exon-exon junction microarrays revealed that transcripts from at least 74% of all multi-exon genes are alternatively spliced in humans. 33 More recently, the availability of high-throughput DNA sequencing technologies allowed an unbiased genomic view of AS. However, estimates on the proportion of genes undergoing AS still widely range from 30 to 95%. 34, 35 Even though it is now perceived that most AS events are nonfunctional, and might reflect a stochastic noise in the splicing process, alternative isoforms enriched in some characteristics like conservation across evolution, tissue specificity, coding frame preservation, abundance, and changes in functional regions of the protein, are likely to have a function. 36 Judgment on the physiologic role of AS is further complicated by the fact that even prematurely terminated transcripts have been shown to participate in gene expression regulation via coupling to the NMD degradation pathway. [21] [22] [23] Concerning the F11 gene, the existence of AS isoforms has been known for many years. 6, 10, 26 Unfortunately, information on the splicing pattern of this gene is still unclear, if not misleading. In fact, most nucleotide and protein databases still report the existence of a "FXI isoform 2", lacking amino acids from 91 to 144, 10, 37 notwithstanding that this isoform was not confirmed by more recent literature 5, 25 and the relevant reference sequence (NM_019559.2) was removed from
GenBank because of insufficient supporting data. This situation, besides illustrating the laboriousness of the process of amending erroneous or unclear data in the highly redundant biomedical web databases, underlines the need to investigate in depth the actual splicing pattern of this gene.
A comprehensive analysis of the F11 splicing pattern, performed by an RT-PCR-based strategy covering the whole gene, revealed the existence of at least 5 AS events, all involving the skipping of 1 or 2 exons. All transcripts were confirmed to be present either in human liver or in platelets. Therefore, we decided to measure its relative amount over the "wild-type" splicing by comparing the absolute quantities of the 2 transcripts in liver and platelets. A striking difference was observed between the 2 samples, with the alternative isoform being almost as abundant as the "wild-type" one in platelets (figure 3d). In the light of the very low level of global F11 transcription in platelets, instead of representing a true tissue-specific AS, the high level of Δ6/7 mRNA might reflect a lower efficiency in the control of accurate splicing. In fact, very recent data on AS on a global scale, suggest that the amount of noisy splicing in a given gene is directly proportional to the number of introns and inversely proportional to its transcription level; in the latter case probably reflecting a tolerance of cells to under-expressed erroneously spliced mRNAs. 36 Concerning the 3 out-of-frame AS transcripts, we explored their possible modulation by the NMD pathway. HepG2 cells treated with the NMD inhibitor drug puromycin were used as a cellular model system to study the susceptibility of PTC+ F11 mRNAs to NMD degradation. The obtained results confirmed that all transcripts containing a PTC were upregulated following NMD inhibition.
Moreover, treatment with puromycin also caused a significant increase in the total amount of F11 mRNA, as assessed by amplifying an mRNA region spanning the last 2 exons, which are expected to be present in almost all transcripts. These data suggest that the coupling of AS and NMD might participate in the post-transcriptional regulation of the F11 gene expression. Indeed, downregulation of PTC+ mRNAs can be particularly important for a dimeric protein, for which even heterodimers carrying a single mutant subunit might lead to potentially deleterious dominant-negative effects.
Among F11 AS transcripts, the most interesting at the protein level was by far the one resulting from the skipping of exons 6+7. In fact, this isoform is not only relatively abundant, but it is also predicted to produce a FXI protein lacking an entire apple domain and having a chimeric A2-A3 domain.
Truncated proteins and chimeras in which the truncation or ligation sites coincide with interfaces between domains are known to be more likely to keep secretion competence. 38 In this view, we explored whether recombinant Δ6/7 FXI retains the potential to be secreted by COS-1 cells.
In contrast with what is reported in the literature, 6 small amounts of Δ6/7 FXI were immunoprecipitated from culture media, demonstrating that this protein isoform can dimerize and be secreted by cells, even though with reduced efficiency. Conversely, it is likely that the wt/Δ6/7
heterodimer is largely retained in the ER, as confirmed by the level of FXI antigen measured in conditioned media of cells coexpressing the two FXI isoforms (38% vs. the expected 50%; figure   5a , left). The increased intracellular levels of FXI molecules containing the Δ6/7 isoform (figure 5a, right), suggest that the lower secretion efficiency is not completely balanced by intracellular degradation.
The absence of the C-terminal half of the A2 and of the N-terminal half of the A3 domains is predicted to completely abolish FXI binding to its substrate FIX , 39,40 therefore it was not surprising to find that the recombinant Δ6/7 protein had no measurable activity (figure 5b). The specific activity measured in media conditioned by cells coexpressing wild-type and Δ6/7 FXIs was significantly higher than 50%. This is quite compatible with a total absence of activity of the deleted isoform, when considering the higher efficiency of secretion of the wild-type homodimer over the mutant homo-or heterodimer. 
